Comparison of antibiotic susceptibility of Escherichia coli between community-acquired and post-prostate biopsy acute bacterial prostatitis.
To compare the antibiotic susceptibility of Escherichia coli (E. coli) between community- acquired acute bacterial prostatitis (CA-ABP) and ABP following transrectal ultrasound-guided prostate biopsy (Bx-ABP). A total of 4,383 patients underwent prostate biopsy from January 2005 to June 2014. Among these patients, 34 had Bx-ABP; of which 22 patients had E. coli identified in their urine or blood culture. E. coli was also identified in 91 out of 209 patients with CA-ABP in urine or blood culture. We investigated patient and microbiological characteristics. The Bx-ABP (59.1%) group showed a higher bacteremia prevalence than the CA-ABP group (13.2%) (p<0.001). Significant differences in the antibiotic sensitivity to E. coli between the two groups were observed for fluoroquinolone, cephalothin, and gentamicin. The antibiotic sensitivity of fluoroquinolone in the Bx-ABP group was only 27.3%. Amikacin, imipenem, meropenem, amoxicillin/clavulanic acid, and piperacillin/ tazobactam showed more than 95% antibiotic sensitivity in both groups. Bx-ABP was an independent predictive factor for bacteremia by multivariate analysis. E. coli in Bx-ABP showed a higher incidence of antibiotic resistance and bacteremia than those in CA-ABP. Carbapenem may be a treatment of choice for patients suspected of having sepsis. Considering the recent emergence of carbapenem-resistant bacteria, piperacillin/tazobactam or amikacin may be considered.